INPP5D and B-cell chronic lymphocytic leukemia: In addition, none of the previously reported SLAMF receptor-interacting signaling molecules (SHP1/2, SHiP1/2) [10] could be confirmed to mediate the BCR pathway antagonistic effects in our CLL models.